You are here

ICER

ICER dings Novo's new oral diabetes drug

ICER dings Novo's new oral diabetes drug

Biopharma Dive

oral semaglutide

Boehringer Ingelheim

Flag link:

New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER

New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER

Endpoints

Aimmune Therapeutics

DBV Technologies

Flag link:

Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato

Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato

Fierce Pharma

Flag link:

UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER

UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER

Endpoints

Duchenne Muscular Dystrophy

Sarepta Therapeutics

Flag link:

ICER seeks to make drug price research more accessible

ICER seeks to make drug price research more accessible

Biopharma Dive

Flag link:

ICER chastises J&J for overpricing depression drug esketamine ‘where there is such need for treatment’

ICER chastises J&J for overpricing depression drug esketamine ‘where there is such need for treatment’

Endpoints

antidepressants

Flag link:

ICER's Growing Impact On Drug Pricing And Reimbursement

ICER's Growing Impact On Drug Pricing And Reimbursement

Forbes

Flag link:

Should Biogen Investors Be Extra Nervous Right Now?

Should Biogen Investors Be Extra Nervous Right Now?

Motley Fool

Alzheimer's disease

Flag link:

Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER

Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER

Fierce Pharma

spinal muscular atrophy

Flag link:

Drug-Price Watchdog ICER Dives into Trump-Fueled Pharma Rebate Debate

Drug-Price Watchdog ICER Dives into Trump-Fueled Pharma Rebate Debate

Xconomy

Flag link:

ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy

ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy

BioCentury

spinal muscular atrophy

Flag link:

The list of shame no biopharma wants to join

The list of shame no biopharma wants to join

EP Vantage

Flag link:

Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies

Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies

Fierce Pharma

spinal muscular atrophy

alternative payments

Flag link:

Cost watchdog ICER lays out plans to scrutinize pharma's costliest price hikes

Cost watchdog ICER lays out plans to scrutinize pharma's costliest price hikes

Fierce Pharma

Flag link:

ICER to probe for clinical justification of drug price hikes

ICER to probe for clinical justification of drug price hikes

BioCentury

Flag link:

ICER says gene therapy may be more cost effective for spinal muscular atrophy

ICER says gene therapy may be more cost effective for spinal muscular atrophy

Yahoo/Reuters

spinal muscular atrophy

Flag link:

ICER weighing issuing advice on trial design

ICER weighing issuing advice on trial design

BioCentury

clinical trials

Flag link:

Prior authorization limits would be 'reasonable' for CGRP drugs, ICER says

Prior authorization limits would be 'reasonable' for CGRP drugs, ICER says

Biopharma Dive

coverage limits

Flag link:

Thanks to lower-than-expected price, ICER backs Amgen's Aimovig—but only after other meds fail

Thanks to lower-than-expected price, ICER backs Amgen's Aimovig—but only after other meds fail

Fierce Pharma

Flag link:

AbbVie's elagolix could put pressure on budgets, ICER estimates

AbbVie's elagolix could put pressure on budgets, ICER estimates

Biopharma Dive

Flag link:

Pages